Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation

Premium

German biotech firm Protagen announced this week that it has closed a €10 million ($12.7 million) private financing round, which it plans to use to fund expansion of its diagnostics business and clinical validation of several proprietary protein biomarkers.

Using its UNIarray protein array platform, which enables the surveying of up to 400 recombinant human proteins for quantitative analysis of antibody binding, the company plans to focus on the development of serum-based protein biomarker tests for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.

In August 2009, the company received €3.7 million in the first tranche of the investment, which also went towards expanding its work on protein biomarkers for multiple sclerosis and prostate cancer. This week's announcement of the second tranche marks the completion of the €10 million round.

In a statement, Protagen CEO Stefan Muller said the "new financing round will allow us the completion of our current development programs until market launch and to evolve to a preferred partner for out-licensing opportunities within the diagnostic industry."

This June, Protagen announced the signing of a cooperation contract with Bayer Schering for the discovery of protein biomarkers for endometriosis (PM 06/11/2010).

Currently it also has in-house research programs investigating diagnostics for breast, ovarian, colon, and pancreatic cancer as well as rheumatoid arthritis, juvenile idiopathic arthritis, Parkinson's disease, and Alzheimer's.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.